Gilead Sciences, Inc. $GILD Shares Sold by Deutsche Bank AG

Posted by Stanley Muller on Jun 10th, 2026

Gilead Sciences logo Deutsche Bank AG cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 30.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,193,754 shares of the biopharmaceutical company’s stock after selling 2,761,535 shares during the period. Deutsche Bank AG’s holdings in Gilead Sciences were worth $760,221,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Paulson Wealth Management Inc. grew its holdings in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares in the last quarter. Essex Financial Services Inc. grew its holdings in shares of Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares in the last quarter. Alpha Cubed Investments LLC grew its holdings in shares of Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares in the last quarter. Personal CFO Solutions LLC grew its holdings in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research reports. Rothschild & Co Redburn dropped their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. TD Cowen lifted their price objective on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Argus lifted their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Finally, Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $156.93.

Get Our Latest Stock Report on Gilead Sciences

Gilead Sciences Stock Down 2.0%

Shares of Gilead Sciences stock opened at $125.50 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The company has a 50 day moving average of $134.03 and a 200 day moving average of $134.37. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $155.82 billion, a P/E ratio of 17.10 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is currently 44.69%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at $81,185,357.82. This represents a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 68,000 shares of company stock worth $9,047,570. 0.30% of the stock is currently owned by insiders.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Gilead and Merck reported positive Phase 3 results for their once-weekly oral HIV regimen, islatravir/lenacapavir, meeting the primary efficacy endpoint in both ISLEND trials. This is important because it supports Gilead’s HIV franchise, which is a major driver of the company’s business. Article Title
Positive Sentiment: Analysts and media coverage highlighted that the successful once-weekly HIV tablet could strengthen Gilead’s core growth outlook, since a more convenient regimen may help expand or defend market share in HIV treatment. Article Title
Neutral Sentiment: Gilead and Merck also discontinued a Phase 3 lung cancer study of Trodelvy plus Keytruda after it failed to show a statistically significant progression-free survival benefit. The trial stop is disappointing, but it mainly affects Gilead’s oncology ambitions rather than its larger HIV business. Article Title
Neutral Sentiment: RBC noted a potential longer-term competitive threat from in vivo CAR-T technology, but this looks more like an early-stage strategic risk than a near-term catalyst for the stock. Article Title
Negative Sentiment: At least one report characterized the news as mixed because the HIV win was partially offset by the Trodelvy setback, which may temper investor enthusiasm for Gilead’s broader pipeline. Article Title

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.